Picard Medical, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Richard Fang
- Full Time Employees
- 75
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1992 E Silverlake Road, Tucson, Arizona 85713, USA Tucson AZ United States of America 85713
- IPO Date
- Aug 29, 2025
- CIK
- 0002030617
- Website
- picardmedical.com
- Similar Companies
- Business
- Picard Medical, Inc. (NYSE American: PMI) is a medical technology company that, through its wholly owned subsidiary SynCardia Systems, LLC, develops, manufactures, markets, and sells the SynCardia Total Artificial Heart (TAH), the only U.S. Food and Drug Administration- and Health Canada-approved implantable total artificial heart designed to fully replace the function of a failed human heart in patients with end-stage biventricular heart failure. The SynCardia TAH, available in two sizes (50cc and 70cc), is supported by external drivers including the Companion 2 Driver System for hospital use and the Freedom Portable Driver System for portability; it serves as a bridge-to-transplant therapy, with over 2,100 implants performed at more than 140 hospitals across 27 countries. The company operates primarily in the United States, Canada, Europe, and pursues expansion in regions including China, India, and the Middle East. Founded in 2021 and headquartered in Tucson, Arizona, Picard Medical became a publicly traded entity following its initial public offering in August 2025, which raised approximately $19.5 million in gross proceeds to fund research and development, international market expansion, portable driver enhancements, sales growth, inventory buildup, and debt repayment. In recent developments, the company reported strong revenue growth, including 207% year-over-year increase to $2.13 million in Q2 2025 driven by U.S. product sales and rentals, and Q3 2025 revenues of $1.187 million; it expanded its 2021 Equity Incentive Plan in October 2025 to authorize up to 18 million shares plus warrants, prompting shareholder dilution concerns and a significant stock price decline. Picard Medical targets cardiac transplant-eligible patients at risk of imminent death from advanced heart failure, addressing a global market of over 64 million patients where donor hearts are scarce; SynCardia continues advancing next-generation technology, including in vitro presentations of the fully implantable Emperor TAH at ISMCS 2025 and receipt of a decision to grant its first China patent in early 2025 to support commercialization in high-growth markets.
Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance
Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance
Picard Medical, Inc. (PMI) Shareholder/Analyst Call Prepared Remarks Transcript
Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
The WSJ Leadership Institute Names Philip Morris International Among “Best Companies For the Future”
Kuehn Law Encourages Investors of Picard Medical, Inc. to Contact Law Firm
Perseverance Metals Appoints Isabelle Cadieux as Independent Director
Picard Medical Announces Leadership Transition
U.S. Bank Names Eric Levine to Lead Healthcare Payments
WSJ Intelligence Study: Uniquely Human Skills Deemed "Non-Replicable" in Automated Future
Philip Morris International Announces New Regional Leadership
Philip Morris International Announces New Regional Leadership
Picard Medical and SynCardia to Present New In Vivo Emperor Total Artificial Heart Data and Patient Outcome Research at ASAIO 2026
Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm
Counterfeit Cigarettes Drive EU Illicit Market Above 10% for First Time Since 2014